CMS To Meet With NASPE/HRS, Manufacturers To Review ICD Decision Process
This article was originally published in The Gray Sheet
Executive Summary
Guidant maintains that its MADIT-II trial ethically could not have been extended to provide more evidence of the long-term benefits of ICDs for the entire study population
You may also be interested in...
SCD-HeFT Results Justify Expanded ICD Coverage – Medtronic’s Stanton
A CMS policy restricting ICD national coverage to a subgroup of the SCD-HeFT trial would undermine future clinical trial investment, according to Medtronic's Marshall Stanton, MD
SCD-HeFT Results Justify Expanded ICD Coverage – Medtronic’s Stanton
A CMS policy restricting ICD national coverage to a subgroup of the SCD-HeFT trial would undermine future clinical trial investment, according to Medtronic's Marshall Stanton, MD
Expanded ICD Patient Pool Augured By New Sub-Studies, Design Features
Cardiac rhythm management companies expect their investments in large randomized, controlled trials to spur increased adoption of ICDs this year